Source: BMC Cancer. Unidades: FM, FMRP
Subjects: GLIOMA, NEOPLASIAS CEREBRAIS, SISTEMA NERVOSO CENTRAL, PROTEÍNAS (ESTUDO)
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
GIMENEZ, Marcela et al. Quantitative proteomic analysis shows differentially expressed HSPB1 in glioblastoma as a discriminating short from long survival factor and NOVA1 as a differentiation factor between low-grade astrocytoma and oligodendroglioma. BMC Cancer, v. 15, n. 481, p. (online), 2015Tradução . . Disponível em: https://doi.org/10.1186/s12885-015-1473-9. Acesso em: 28 ago. 2024.APA
Gimenez, M., Marie, S. K., Oba-Shinjo, S., Uno, M., Izumi, C., Oliveira, J. B., & Rosa, J. C. (2015). Quantitative proteomic analysis shows differentially expressed HSPB1 in glioblastoma as a discriminating short from long survival factor and NOVA1 as a differentiation factor between low-grade astrocytoma and oligodendroglioma. BMC Cancer, 15( 481), (online). doi:10.1186/s12885-015-1473-9NLM
Gimenez M, Marie SK, Oba-Shinjo S, Uno M, Izumi C, Oliveira JB, Rosa JC. Quantitative proteomic analysis shows differentially expressed HSPB1 in glioblastoma as a discriminating short from long survival factor and NOVA1 as a differentiation factor between low-grade astrocytoma and oligodendroglioma [Internet]. BMC Cancer. 2015 ; 15( 481): (online).[citado 2024 ago. 28 ] Available from: https://doi.org/10.1186/s12885-015-1473-9Vancouver
Gimenez M, Marie SK, Oba-Shinjo S, Uno M, Izumi C, Oliveira JB, Rosa JC. Quantitative proteomic analysis shows differentially expressed HSPB1 in glioblastoma as a discriminating short from long survival factor and NOVA1 as a differentiation factor between low-grade astrocytoma and oligodendroglioma [Internet]. BMC Cancer. 2015 ; 15( 481): (online).[citado 2024 ago. 28 ] Available from: https://doi.org/10.1186/s12885-015-1473-9
